Selective thromboxane inhibition: a new approach to antiplatelet therapy
Department of Neurology; Department of Medicine, Division of Cardiovascular Medicine
Animals; Cerebrovascular Disorders; Imidazoles; Male; Platelet Aggregation; Swine; Thromboxane B2; Thromboxanes
Medicinal and Pharmaceutical Chemistry | Neurology | Pharmacy and Pharmaceutical Sciences
Antiplatelet drugs as exemplified by aspirin are used frequently to prevent stroke. Aspirin inhibits the formation of both the potent platelet aggregator, thromboxane A2 and the potent anti-aggregator, prostacyclin. Another approach to the inhibition of platelet aggregation might involve selective suppression of thromboxane formation. We report our experience in swine with UK-38,485, a drug which selectively inhibits thromboxane formation. The rationale and potential uses of UK-38,485 in the in vivo prevention of platelet aggregation and for the therapy of cerebrovascular disease are discussed.
Stroke. 1984 Sep-Oct;15(5):813-6.
Stroke; a journal of cerebral circulation
Fisher M, Weiner BH, Ockene IS, Hoogasian JS, Natale AM, Arsenault JR, Johnson MH, Levine PH. (1984). Selective thromboxane inhibition: a new approach to antiplatelet therapy. Neurology Publications and Presentations. Retrieved from https://escholarship.umassmed.edu/neuro_pp/49